{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:55:07Z","timestamp":1792234507273,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jacbts.2016.03.001","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T16:51:57Z","timestamp":1461948717000},"page":"180-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Detection and Management of Geographic Disparities in the TOPCAT Trial"],"prefix":"10.1016","volume":"1","author":[{"given":"Michael R.","family":"Bristow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Silva Enciso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline Murguia","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sopko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Boineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry H.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2016.03.001_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1067\/mhj.2001.117600","article-title":"Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial","volume":"142","author":"Wedel","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacbts.2016.03.001_bib2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jacc.2011.03.057","article-title":"Influence of global region on outcomes in large heart failure \u03b2-Blocker trials","volume":"58","author":"O\u2019Connor","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.03.001_bib3","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/eurheartj\/eht071","article-title":"International differences in treatment effect: do they really exist and why?","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2016.03.001_bib4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMsb0803929","article-title":"Ethical and scientific implications of the globalization of clinical research","volume":"360","author":"Glickman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.03.001_bib5","first-page":"561","article-title":"Race, genetic variation, and therapeutic response disparities in heart failure","volume":"2","author":"Taylor","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacbts.2016.03.001_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajpa.20983","article-title":"How race becomes biology: embodiment of social inequality","volume":"139","author":"Gravlee","year":"2009","journal-title":"Am J Phys Anthropol"},{"key":"10.1016\/j.jacbts.2016.03.001_bib7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacbts.2016.03.001_bib8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.03.001_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2016.03.001_bib10","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2016.03.001_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.03.001_bib12","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jacc.2008.07.056","article-title":"Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program","volume":"52","author":"Blair","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2016.03.001_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/eurjhf\/hfp003","article-title":"The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction","volume":"11","author":"Kub\u00e1nek","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2016.03.001_bib14","first-page":"478","article-title":"Relative importance of history of heart failure hospitalization and N-terminal pro-B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction","volume":"3","author":"Kristensen","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacbts.2016.03.001_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.114.012284","article-title":"International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction","volume":"131","author":"Kristensen","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2016.03.001_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2016.03.001_bib17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2013.1569","article-title":"Defining diastolic heart failure and identifying effective therapies","volume":"309","author":"Cleland","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2016.03.001_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2016.03.001_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/sim.1688","article-title":"Increasing the sample size when the unblinded interim result is promising","volume":"23","author":"Chen","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jacbts.2016.03.001_bib20","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/sim.4102","article-title":"Adaptive increase in sample size when interim results are promising: a practical guide with examples","volume":"30","author":"Mehta","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jacbts.2016.03.001_bib21","unstructured":"Facenda J. Pain is inevitable, on The Power and the Glory: The Original Music and Voices of NFL Films. New York, NY: Tommy Boy Music, 1998; track 25. Available at: http:\/\/www.cduniverse.com\/search\/xx\/music\/pid\/1020022\/a\/power+and+the+glory%3A+music+%26+voices+of+nfl+films.htm. Accessed January 7,\u00a02016."}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X16000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X16000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:17:07Z","timestamp":1762820227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X16000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S2452302X16000346"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2016.03.001","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection and Management of Geographic Disparities in the TOPCAT Trial","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2016.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}